price month
 close
ep rang essenti line issu initi ep guidanc
ahead estim line consensu
revenu growth billion exceed
estim reflect cc core revenu growth nice ahead
plan guidanc impli bp ebitda margin expans
heel expect bp profit ramp cost
initi off-set headwind fx re-affirmed
guidanc assumpt make chang
estim boost ep reflect
stronger underli revenu run rate partial off-set fx
de-tail guidanc assum competitor
combin product million bp revenu tailwind
rel previou estim compet combin parasiticid
expect potenti zoeti outlook also assum
imvixa sea lice salmon launch norway due
regulatori holdup strateg exit sale guidanc million
exceed estim million consensu million
expect manufactur sale human growth hormon humatrop
arrang former parent new restructur
effort includ shift direct presenc distribut model
countri help drive estim ebitda margin expans bp
reiter neutral encourag view respect
outlook constant currenc core revenu growth
exceed plan product agenda slightli ahead
schedul elan share ipo sept vs
 share current trade ebitda premium
view premium justifi ahead meaning
innov profit ramp
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
fourth largest anim health pharmaceut compani
focus develop therapeut supplement
livestock companion anim diversifi portfolio includ
brand market countri
blue sky scenario assum greater expect
adopt product launch expedit pipelin success
meaning profit ramp on-going oper effici
initi specif increment million
annual sale product launch increment bp
oper profit margin expans would drive upsid
current ep estim support blue sky scenario
grey sky scenario assum draconian
fundament backdrop companion product anim health
fundament greater competit headwind new exist
product line lower expect ramp profit
separ parent specif flat top-line growth
bp ramp profit would translat ep
growth contribut grey sky scenario
 close
figur guidanc metric vs cs consensu
factset compani data credit suiss estim million except per share amount
guidanc estimateconsensusguid mid delta vs cs midpoint ep bp ebitda margin expans charl martineau univers toronto
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
